



- (51) **International Patent Classification:**
C07K 14/705 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/GB2020/053247
- (22) **International Filing Date:**
16 December 2020 (16.12.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
1918586.7 17 December 2019 (17.12.2019) GB
- (71) **Applicant: JPV01 LTD** [GB/GB]; 21 Bedford Square,
London, WC1B 3HH (GB).
- (72) **Inventor: PATTERSON, James**; Flat 112 The Belvedere,
Homerton Street, Cambridge, Cambridgeshire, CB2 0NU
(GB).
- (74) **Agent: PILKINGTON, Stephanie Joan**; Potter Clarkson
LLP, The Belgrave Centre, Talbot Street, Nottingham, Not-
tinghamshire, NG1 5GG (GB).

- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

- (54) **Title:** ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT




FIG. 1

- (57) **Abstract:** The present invention provides engineered platelets with chimeric platelet receptors (CPR) with a desired target specificity. Additionally, the engineered platelets may comprise cargo which may be released upon activation of the platelet. Additionally, the platelets may be generated *in vitro* from megakaryocytes engineered to generate non-thrombogenic platelets.

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*